BeiGene has announced the opening of its new US biologics manufacturing and clinical research and development (R&D) facility at Hopewell, New Jersey.
Situated at the Princeton West Innovation Campus, the site is set to play a crucial role in providing innovative medicines to cancer patients worldwide.
Go deeper with GlobalData
Dedicated to commercial-stage biologic pharmaceutical manufacturing, the new facility spans 42 acres and is designed with the flexibility to scale production to meet current and future demands.
BeiGene investment of $800m in the facility is the result of a three-year project aimed at enhancing its manufacturing and R&D capabilities in the US.
By the end of 2025, the site is expected to generate hundreds of high-tech employment opportunities.
This strategic development will support BeiGene’s rapidly maturing pipeline.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBeiGene currently has more than 30 molecules at various stages of clinical and commercial development.
Its oncology pipeline includes new treatments such as targeted degraders, antibody-drug conjugates, monoclonal antibodies and traditional small molecules.
These therapies have the potential to combat 80% of the world’s cancers.
BeiGene’s latest expansion enhances its research and clinical development capabilities and ensures production scalability.
The strategic move is aimed at lowering costs, bolstering supply chain resilience, mitigating the impact of global disruptions, safeguarding production capacity and swiftly adapting to new innovative modalities.
BeiGene John Oyler co-founder, chairman and CEO stated: “BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients.
“We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent. We look forward to deepening our relationships with key regional research institutions as we advance our robust pipeline of next-generation haematology and solid tumour medicines and continue to emerge as a leading global oncology innovator.”
In March 2024, the US Food and Drug Administration (FDA) approved BeiGene’s TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or metastatic oesophageal squamous cell carcinoma after previous systemic chemotherapy.
